× Digital News Videos Health & Science Lifestyle Opinion Education Columnists Moi Cabinets Arts & Culture Fact Check Podcasts E-Paper Lifestyle & Entertainment Nairobian Entertainment Eve Woman Health Magazine TV Stations KTN Home KTN News BTV KTN Farmers TV Radio Stations Radio Maisha Spice FM Vybez Radio Enterprise VAS E-Learning Digger Classified Jobs Games Crosswords Sudoku The Standard Group Corporate Contact Us Rate Card Vacancies DCX O.M Portal Corporate Email RMS
×
Men
menu search
Standard Logo
Home / Health & Science

Research: More are faithful to ARV drugs

HEALTH & SCIENCEBy PROTUS ONYANGO | Mon,May 29 2017 00:00:00 EAT
By PROTUS ONYANGO | Mon,May 29 2017 00:00:00 EAT

 Antiretroviral drugs.  (Photo: Courtesy)

With antiretroviral drugs and patients' persistence in taking them, HIV has become a manageable chronic condition.

A study by Brown University that examined a national sample showed that the median duration of persisting with treatment increased by more than 50 per cent between 2001 and 2010.

"This shows that a lot of people are not dying or infecting others," said Ira Wilson, corresponding author of the study and chairperson of the Health Services Policy and Practice Department.

Very real benefits

Dr Wilson said the differences represent tremendous and very real benefits.

Graduate student Bora Youn led the research that tracked 43,598 HIV patients in 14 states over the decade.

Persistence refers to the time from starting treatment to discontinuing it. The study also compared those rates to persistence with medications for other chronic conditions among thousands of patients without HIV-infection.

Between 2001 and 2003, half of the patients stopped taking HIV medications 24 months after starting them, but between 2004 and 2006 the period of persistence reached 35.4 months.

In the final study period, 2007-2010, more than half the patients were still taking the medications, therefore the median had not been reached.

"Some studies have shown a similar trend but they have been based on data from individual clinics. This study is the first to show progress among a broad-based, low-income population," Wilson said.

Related Topics

Share this story
.
RECOMMENDED